Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Plasma protein-profiling to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC)

ABSTRACT: Plasma protein expression patterns can be used as prognostic biomarkers in various types of cancer. We aimed to identify a protein-based signature for distant metastatic risk assessment in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC).

ORGANISM(S): Homo sapiens

PROVIDER: GSE149587 | GEO | 2020/09/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

LncRNA expression-profiling to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma

Project description:LncRNAs can be used as prognostic biomarkers in various types of cancer. We aimed to identify a lncRNA expression pattern for individual distant metastatic risk assessment in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC).

2022-04-10 | GSE180272 | GEO

Gene expression-profiling to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma

Project description:Gene expression patterns can be used as prognostic biomarkers in various types of cancer. We aimed to identify a gene expression pattern for individual distant metastatic risk assessment in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC).

2019-05-02 | GSE103611 | GEO

CircRNA expression-profiling to predict prognosis in locoregionally advanced nasopharyngeal carcinoma

Project description:CircRNAs serve as prognostic biomarkers in various types of cancer. We aimed to identify a circRNA signature for individual relapse risk assessment in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC).

2023-12-21 | GSE190271 | GEO

Gene expression-profiling to predict induction chemotherapy efficacy in locoregionally advanced nasopharyngeal carcinoma

Project description:Gene expression signature can be used to predict treatment efficacy in various types of tumour. We aim to identify a gene expression signature to predict efficacy of induction chemotherapy (IC) in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC).

2021-04-14 | GSE132112 | GEO

Plasma protein-profiling to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC)

Project description:Plasma protein-profiling to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC)

| PRJNA629317 | ENA

LncRNA expression-profiling to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma

Project description:LncRNA expression-profiling to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma

| PRJNA747297 | ENA

Gene expression-profiling to predict induction chemotherapy efficacy in locoregionally advanced nasopharyngeal carcinoma

Project description:Gene expression-profiling to predict induction chemotherapy efficacy in locoregionally advanced nasopharyngeal carcinoma

| PRJNA545965 | ENA

Nasopharyngeal carcinoma (NPC) cell lines

Project description:5 EBV-free nasopharyngeal carcinoma cell lines expression patterns again normal epithelial tissues.

2010-06-09 | E-GEOD-2370 | biostudies-arrayexpress

Nasopharyngeal carcinoma (NPC) cell lines

Project description:5 EBV-free nasopharyngeal carcinoma cell lines expression patterns again normal epithelial tissues. Keywords: repeat sample

2005-06-07 | GSE2370 | GEO

Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma.

Project description:The value of adding induction chemotherapy (IC) to concurrent chemoradiotherapy (CCRT) for the treatment of locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear. In our recent article entitled "Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial" published in the Lancet Oncology, we reported the results of a phase III, multicenter, randomized controlled trial comparing cisplatin, 5-fluorouracil, and docetaxel (TPF) IC plus CCRT versus CCRT alone in patients with T3-4N1/TxN2-3M0 NPC (ClinicalTrials.gov registration number NCT01245959). The IC-plus-CCRT group showed significantly higher 3-year failure-free survival, overall survival, and distant failure-free survival rates than the CCRT-alone group, with an acceptable toxicity profile. Our study suggests that adding TPF IC to CCRT could increase survival rates and reduce distant failure in patients with locoregionally advanced NPC. However, long-term follow-up is required to assess the eventual efficacy and toxicity of this strategy, and a more accurate method to determine prognosis is needed to enable better tailoring of treatment strategy for individual patients.

| S-EPMC5111216 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data